EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, AFT Pharmaceuticals's Enterprise Value is NZ$452.7 Mil.
AFT Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was NZ$-19.3 Mil. Therefore, AFT Pharmaceuticals's EV-to-FCF for today is -23.46.
The historical rank and industry rank for AFT Pharmaceuticals's EV-to-FCF or its related term are showing as below:
NZSE:AFT'
s EV-to-FCF Range Over the Past 10 Years
Min: -172.78 Med: 4.86 Max: 176.07
Current: -23.46
During the past 11 years, the highest EV-to-FCF of AFT Pharmaceuticals was 176.07. The lowest was -172.78. And the median was 4.86.
NZSE:AFT's EV-to-FCF is ranked worse than 100% of 562
companies
in the Drug Manufacturers industry
Industry Median: 20.955
vs NZSE:AFT: -23.46
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
AFT Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
AFT Pharmaceuticals's share price for today is NZ$3.91.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. AFT Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was NZ$0.140.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
AFT Pharmaceuticals EV-to-FCF Related Terms
AFT Pharmaceuticals EV-to-FCF Historical Data
* Premium members only.
The historical data trend for AFT Pharmaceuticals's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, AFT Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AFT Pharmaceuticals EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AFT Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where AFT Pharmaceuticals's EV-to-FCF falls into.
AFT Pharmaceuticals's current Enterprise Value is NZ$452.7 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. AFT Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was NZ$-19.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AFT Pharmaceuticals (NZSE:AFT) has a EV-to-FCF of -23.46 as of Jul. 12, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on AFT Pharmaceuticals and its competitors. According to the industry distribution chart, AFT Pharmaceuticals ranks #999999 out of 562 companies in the Drug Manufacturers industry.
Is AFT Pharmaceuticals' EV-to-FCF too high?
AFT Pharmaceuticals' current EV-to-FCF is -23.46. Based on the distribution chart, AFT Pharmaceuticals ranks #999999 out of 562 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, AFT Pharmaceuticals has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does AFT Pharmaceuticals' EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, AFT Pharmaceuticals ranks #999999 out of 562 companies for EV-to-FCF. This places AFT Pharmaceuticals in the lower half of its industry. The industry median EV-to-FCF is 20.96. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.96, based on 562 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on AFT Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AFT Pharmaceuticals's current EV-to-FCF is -23.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AFT Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, AFT Pharmaceuticals (NZSE:AFT) is currently considered Fairly Valued. The stock's GF Value™ is NZ$4.18, compared to a current price of NZ$3.91 — trading 6.5% below its estimated fair value. The current EV-to-FCF is -23.46. AFT Pharmaceuticals' overall GF Score™ is 95/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For AFT Pharmaceuticals (NZSE:AFT), the current EV-to-FCF is -23.46 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AFT Pharmaceuticals (NZSE:AFT) Overvalued in 2026?
Based on GuruFocus' analysis, AFT Pharmaceuticals stock appears to be undervalued.
The current stock price of NZ$3.91 is trading 6.5% below its estimated GF Value™ of NZ$4.18.
GuruFocus considers AFT Pharmaceuticals to be Fairly Valued.
Key valuation signals for NZSE:AFT:
EV-to-FCF: -23.46
GF Value™: NZ$4.18 vs. price of NZ$3.91 (6.5% below fair value)
No single metric tells the full story. See the NZSE:AFT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Maxigesic dose forms, Capsaicin creams, Crystaderm, Kiwisoothe, Micolette, and others. The group has four operating segments based on geographical location being Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia, which includes the sales and distribution activity relating to the Australian market.
95GF Score
Get the complete analysis for NZSE:AFT
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NZSE:AFT has been successfully added to your 
